The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
David Planchard
No relevant relationships to disclose
Julien Mazieres
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Celgene; Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Millennium; Novartis; Pfizer
Charles M. Rudin
Consultant or Advisory Role - AVEO; Lilly; Oncothyreon
Fabrice Barlesi
No relevant relationships to disclose
Elisabeth A. Quoix
No relevant relationships to disclose
Pierre Jean Souquet
Honoraria - GlaxoSmithKline
Mark A. Socinski
Research Funding - GlaxoSmithKline
Julie Switzky
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Bo Ma
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vicki L. Goodman
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Stanley W. Carson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Martin Curtis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael R. W. Streit
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Transgenomic
Stock Ownership - KEW Group
Honoraria - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Transgenomic
Other Remuneration - Response Genetics